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Plasma lipids and acyltransferase activities in experimental
nephrotic syndrome
TERESA L. SESTAK, NAHID ALAvI', and PAPASANI V. SUBBAIAH
Rush Medical College, Departments of Medicine and Biochemistry, Chicago, Illinois, USA
Plasma lipids and acyltransferase activities in experimental nephrotic
syndrome. Lecithin:cholesterol acyltransferase (LCAT) and lysoleci-
thin acyltransferase (LAT) are two activities carried out by the same
plasma enzyme, but require different apoprotein activators. The LCAT
reaction takes place primarily on high density lipoproteins (HDL) and is
activated by serum albumin, whereas LAT takes place on low density
lipoproteins (LDL) and is inhibited by albumin. In nephrotic syndrome
(NS), the levels of serum albumin are reduced, whereas the LDL levels
are increased, and therefore, the ratio of LAT/LCAT activities should
be increased. To test this hypothesis, we estimated the lipid levels and
the two enzyme activities in experimental NS induced in rats by the
injection of anti-FxIA antibody (passive Heymann nephritis). As found
in other nephrotic conditions, the plasma lipid levels rose progressively
as the proteinuria increased and the serum albumin concentration
declined. In addition, the ratio of LAT/LCAT activities increased by
about fourfold after nine days of induction of nephritis. The LCAT
activity correlated positively and the LAT activity negatively with
serum albumin levels. The esterified cholesterol correlated positively
with LCAT activity in normal rats but negatively in nephrotic animals,
indicating that most of the cholesteryl esters in NS may be non-LCAT
derived. The free cholesterol/lecithin ratio, a known risk factor for
atherosclerosis, increased significantly in nephrotic rats. Furthermore,
since the increase in the LAT activity produces more disaturated
lecjthjns, another putative risk factor, the cumulative risk of coronary
heart disease may be increased in long-term NS.
The clinical manifestations of nephrotic syndrome (NS) in-
clude heavy proteinuria, hypoalbuminemia, generalized edema
and hyperlipidemia. In these patients, elevated levels of cho-
lesterol, very low density lipoproteins (VLDL), low density
lipoproteins (LDL), are seen along with low or normal high
density lipoproteins (HDL) [1]. The cause of hyperlipidemia in
NS, as well as its putative role in the increased risk of
atherosclerosis in nephrotic patients has not been established.
Currently, it is believed that the enhanced hepatic synthesis of
lipoproteins in response to the hypoalbuminemia and conse-
quent low serum oncotic pressure is the underlying cause of
hyperlipidemia. A defect in lipoprotein catabolism has also
been proposed by Valeri, eta! [1], whereas Diamant and Shafrir
[2] suggested other possibilities, such as a shift of preformed
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lipids from the liver into the circulation, mobilization of adipose
tissue fatty acids, and an increased activity of rate limiting
enzymes in the lipogenesis pathway. A loss of HDL in the urine
of NS patients is thought to occur due to its smaller size and
thus account for its reduced serum level [3]. The low HDL level
is believed to be a determining risk factor for atherosclerosis [4]
and lead many to postulate that this predisposes NS patients to
premature atherosclerosis [1]. In fact, Berlyne and Mallick [5]
observed that the incidence of ischemic heart disease is 85 times
greater in the NS than in the general population, although this
has been questioned by others [6].
Lecithin-cholesterol acyltransferase (LCAT) is responsible
for the formation of most of the cholesteryl esters in human
plasma [7] by catalyzing the transfer of a fatty acid from the sn-2
position of lecithin to the 3-OH position of cholesterol. It is
activated by apolipoprotein A-I and takes place predominantly
on the surface of certain HDL particles. This enzyme has also
been shown by our laboratory to have lysolecithin acyltransfer-
ase (LAT) activity which acylates lysolecithin to lecithin [81.
This reaction, in contrast to the LCAT reaction, requires LDL
and appears to enrich the plasma with disaturated lecithins [9],
a high concentration of which has been implicated as an
independent risk factor for atherosclerosis [10]. Normally,
serum albumin stimulates the LCAT reaction but inhibits the
LAT reaction by binding and removing its substrate, lysoleci-
thin. Therefore, in NS, where there is decreased HDL, in-
creased LDL and decreased albumin, an alteration in the ratio
of the two enzyme activities should occur, and we tested this
hypothesis in the present study.
Although the lipid abnormalities present in NS have been
studied in puromycin aminonucleoside-induced rat model [2],
the possible direct effects of the nucleoside on the liver and
other tissues [11] make this model unsuitable to study the effect
of NS alone on lipoprotein metabolism. Therefore, we exam-
ined these activities in a rat model with passive Heymann
nephritis in which NS is induced by the injection of anti-Fx1A
antibodies which have been produced in sheep. No direct
effects of the antibody on the liver are seen in this model [12].
The results presented here show that the ratio of LAT/LCAT
activities did increase significantly in passive Heymann nephri-
tis, as did the plasma lipid concentrations. A significant increase
in the unesterified cholesteroL/lecithin ratio of plasma, a re-
cently observed atherogenic risk factor [13], was also seen.
These results provide further proof of the physiological rele-
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vance of the LAT activity and indicate the possible increased
risk of development of atherosclerosis in NS patients.
Methods
Animals and treatment
Male Sprague-Dawley rats (8 weeks old and weighing 200 to
250 g) were purchased from Harlan Commercial Breeding
(Indianapolis, Indiana, USA). The animals were fed a standard
rat chow (Purina, St. Louis, Missouri, USA).
The rats were injected with one ml of sheep-anti-FxlA
antibody diluted 1:1 with normal, non-immune sheep serum, via
the tail vein. The anti-Fx1A antibody was obtained from Dr.
Bernice Noble of State University of New York at Buffalo and
the preparation of this antibody has been described before [141.
Control rats were injected with the same volume of normal,
non-immune sheep serum. The individual animals were placed
in metabolic cages 24 hours prior to their sacrifice and urine
specimens were collected during this period, when they had
free access to tap water but the food was withdrawn. The next
day, the blood was drawn from these fasting rats via the inferior
vena cava. Blood was collected in EDTA-containing tubes (1
mg/mi) for enzyme assays and protein and creatinine determi-
nations. A wedge section from kidney and liver (in some rats)
were obtained for immunofluorescence study. The nephrotic
rats were studied at Days 0, 3, 6, and 9 post-injection, while the
control rats were included only at Day 3 and Day 9. For
comparison purposes, the Day 0 nephrotic animals and Day 3
and Day 9 control animals were grouped together as the control
group (Day 0).
Urinary protein excretion was measured in a 24-hour urine
collection by using the Bradford method [15], with human
serum albumin as the standard. Urinary and plasma creatinine
was measured by an autoanalyzer (Beckman Instruments, Palo
Alto, California, USA). Hematocrit values were determined
using a heparinized capillary tube. Fresh plasma was used for
the enzyme assays on the same day of the experiment, while
plasma neutral and phospholipids were determined upon com-
pletion of the time course, until which time the samples were
stored at —70°C. Serum albumin was measured by bromcresol
green binding [161 in a Hitachi autoanalyzer at 600 nm.
Enzyme assays
The LAT activity of the plasma was measured as described
earlier [17] except that [1-'4C]-palmitoyl lysophosphatidyl
choline was used as substrate. The substrate (for 24 assays) was
prepared by mixing 1 jsCi of lysopalmitoyl phosphatidylcholine
(0.01 mCi/mmol, New England Nuclear DuPont, Wilmington,
Delaware, USA) and 7.2 jimol of unlabelled 1-palmitoyl
lysophosphatidylcholine in 1.8 ml chloroform, drying under
nitrogen and dispersing in 2.4 ml of 10 msi Tris-0.15 M NaC1-l
mM EDTA, pH 7.4 by vortexing. The reaction mixture con-
tained 0.3 mol of lysolecithin, 2.5 smol of 2-mercaptoethanol,
10 ifiM Tris, 0.15 M NaCl, 1 m EDTA and 0.1 ml of plasma
(added last) in a final volume of 0.4 ml. Each plasma sample was
assayed in duplicate, and control reactions containing no
plasma were run simultaneously. The samples were incubated
at 37°C for two hours and the reaction stopped with the addition
of 1 ml methanol. The lipids were extracted by the Bligh and
Dyer procedure [18]. Upon drying the chloroform extracts, the
lipids were redissolved in 100 !d chloroform and the entire
extract spotted onto activated silica gel plates (Whatman,
American Scientific Products, McGaw Park, Illinois, USA),
and the plates developed in the solvent system of chloroform:
methanol:water (65:25:4 by volume). The lipids were visualized
by a brief exposure to iodine vapors. The lecithin and lysolec-
ithin spots were scraped and the radioactivity determined in a
Beckman LS-7000 liquid scintillation counter after adding 0.5
ml water and 5.0 ml Aquamix scintillation fluid (ICN Radio-
chemicals, Irvine, California, USA). The radioactivity in the
samples was corrected for quenching using the H number
(Beckman Instruments) to convert cpm into dpm. LAT activity
was expressed as nmoles of lysolecithin converted to lecithin/
ml plasma/hr (molar esterification rate or MER), or as percent
of lysolecithin acylated/hr (fractional esterification rate or
FER).
The LCAT assay was performed essentially as described by
Stokke and Norum [19], with the labelled cholesterol equili-
brated with the endogenous cholesterol as the substrate. The
reaction was carried out, in a final volume of 0.17 ml, for 30
minutes at 37°C and stopped by the addition of 0.23 ml 5%
trichioroacetic acid and 1.0 ml methanol. The total lipids were
extracted [181, cholesterol and cholesteryl ester separated by
TLC using the solvent system of petroleum ether:ethyl acetate
(85:15) and the radioactivity determined in the scintillation
counter. The enzyme activity was expressed as percent of free
cholesterol esterified/hour (FER) or as smoles of cholesterol
esterified/hour/mI plasma (MER).
Lipid analyses
Total plasma cholesterol was measured using an enzymatic
reagent kit (Boehringer-Mannheim, Indianapolis, Indiana,
USA) while unesterified cholesterol was measured using a
working solution similar to the above kit except that cholesteryl
ester hydrolase was omitted. The total plasma triglycerides
were assayed by a GPO-Trinder kit (Sigma Diagnostics, St.
Louis, Missouri, USA). The phospholipids were quantitated by
phosphorus estimation using a modified Bartlett procedure [20]
after separation on TLC plates, with the solvent system chlo-
roform: methanol: water (65:25:4 by volume).
Immunofluorescence
Kidneys were examined by immunofluorescence for deposi-
tion of anti-FxlA antibodies as described by Singh and
Schwartz [21].
Lipoprotein separation
Plasma (500 d) was layered in between sodium bromide
solutions with densities of 1.149 g/ml and 1.021 gIml, and the
lipoproteins were separated by density gradient centrifugation
at 15°C in a Beckman SW-4l Ti swinging bucket rotor for 66
hours at 38,000 rpm in a Beckman L5-65 ultracentrifuge, by a
modification of the method outlined by Cabana, Siegel and
Sabesin [22]. The fractions (0.6 ml) were collected using an Isco
Model 640 gradient fractionator, analyzed at 280 nm to give a
continuous protein absorbance profile and recorded on accom-
panying chart paper. Total cholesterol and triglycerides were
estimated in aliquots of each fraction by enzymatic methods
described above.
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Fig. 1. Time course of development of nephrotic syndrome after injec-(ion of anti-FxJA, On Day 0, the rats were injected with 1 ml of
anti-Fx1A preparation diluted 1:1 with non-immune sheep serum.
Urinary protein was collected over a 24-hr period before sacrifice and
the protein estimated by the Bradford procedure [151. Serum albumin
was estimated by the bromcresol green method [16]. The Day 0 values(N = 11) included both control animals injected with non-immune
serum and the animals injected with anti-FxIA, but sacrificed immedi-
ately thereafter. The number of animals at other time intervals were five
each on Day 3 and Day 6, and six on Day 9.
Fig. 2. Neutral lipid concentrations of plasma during the development
of passive Heymann nephritis. Rats were injected with anti-FxIA
serum on Day 0 and sacrificed on Days 0, 3, 6 or 9. The blood was
collected in EDTA tubes (I mg/mi) and the plasma prepared by
centrifugation. Free cholesterol (FC) •—•, esterified cholesterol (EC)
0—0, and triglycerides (TG) A—A were estimated using enzymatic
kits as described under Methods. All lipid values given are mean SD.
To convert into mg/dl, multiply by 38.7 for FC and EC and by 88.5 for
TG. < 0.01, **<o.ool, compared to Day 0 values,
Data analysis
Standard statistical methods were used to determine the
significance of the differences (Student's t-test) and of the
correlation coefficients [231. Curve fitting of various parameters
was done by the least square regression method using a
computer program (Slide Write Plus, Advanced Graphics Soft-
ware, Sunnyvale, California, USA), with either linear or power
fit formulas.
Results
Time course of the development of nephrotic syndrome
Proteinuria developed three days after injection of anti-Fx 1 A
serum into the rats (Fig. 1). The serum albumin concentrations
decreased in parallel to the development of proteinuria. Since
the magnitude of proteinuria varied from one batch of antibody
Table 1. Ratios of plasma lipids before and after induction of passive Heymann nephritis
Lipid ratio
Days after injection
0 (control)(N = II) 3(N = 5) 6(N = 5) 9(N = 6)
FCIPC
FCIEC
TC/TG
LPC/PC
Sph/PC
0.571 0.125
0.403 0.266
6.027 4.293
0.640 0.119
0.209 0.044
0.596 0.123
0.378 0.183
5.159 2.296
0.710 0.065
0.211 0.026
0.660 0.101
0.410 0.157
6.432 1.531
0.488 0.058
0.199 0.036
0.762 0.078*
0.503 0.206
3.432 1.403
0.302 0,102**
0.151 0.022*
5
PHN was induced by injection of sheep anti-Fx1A antibody into rats on Day 0. The Day 0 values include four animals sacrificed immediately
after injection of anti-Fx1A and seven control animals, which were injected with non-immune sheep serum and sacrificed on Day 3 or after Day
9. All values are mean SD.
aP < 0.05, when compared to Day 0 values.b p < 0.005, when compared to Day 0 values.
Abbreviations are: EC, esterified cholesterol; FC, free cholesterol; LPC, lysophosphatidyl choline PC, phosphatidyicholine; Sph, sphingomy-
elm; TC, total cholesterol; TG, triglycerides.
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Fig. 3. Phospholipid composition of plasma during the development of
passive Heymann nephritis. Plasma lipids were extracted [18] and the
PC (•, phosphatidyl choline or lecithin), LPC (0, lysophosphatidyl
choline or lysolecithin), SPH (•, sphingomyelin) and PE (A, phosphati-
dyl ethanolamine) were separated by TLC and the lipid phosphorus
determined as described under Methods. All values shown are mean
SD. *D < 0.05, **<O 005, compared to Day 0 values.
to another, all the results presented here are from a single batch
of antibody. The extent of proteinuria was comparable to that
obtained with puromycin aminonucleoside injections [2, 11].
Average hematocrit values changed from 41% on Day 0 to 36%
on Day 9 after antibody injection. Creatinine clearance was
found to be 2.22 0.3 mI/mm in control rats and 1.53 1.7
ml/min in nephrotics.
Immunofluorescence staining of the kidney sections revealed
deposition of the antibody, in a granular pattern, as early as one
hour after injection. In one experiment, we treated the anti-
serum used with dried powders of rat liver or kidney prepara-
tions prior to injection into the animals, to test if the hyperlip-
idemia produced was due to a direct effect of the antibody on
the liver. No significant changes in lipemia or proteinuria were
observed when the antiserum was adsorbed with liver powder,
but both lipemia and proteinuria were significantly reduced
after adsorption with kidney powder, indicating that the effects
observed here were due to specific effects of antibody on the
kidney.
Plasma lipid levels
Figure 2 shows the effects of passive Heymann nephritis on
the neutral lipid concentrations of the plasma. There was a
steady increase in free cholesterol, esterified cholesterol and
triglycerides after three days. The relative increase in the
cholesterol levels was lower than the triglycerides and therefore
the total cholesterolltriglyceride (TC/TG) levels fell by about
50% after nine days (Table 1). The effect of passive Heymann
nephritis on the phospholipid concentrations is shown in Figure
3. Although both lysolecithin and lecithin increased, the rise in
lecithin was more striking, and therefore the lysolecithin/leci-
thin (LPC/PC) ratios fell significantly after nine days (Table 1).
The increase in sphingomyelin was also less marked compared
to that of lecithin. There was a twofold increase in phosphati-
dylethanolamine (PE) concentration, but the levels of this
phospholipid were very low to start with. Although we detected
phosphatidyl serine and phosphatidyl inositol spots on the TLC
plates, the amounts of these lipids were too small to measure
accurately by the lipid phosphorus. The ratio of free choles-
terol/lecithin (FC/PC), a putative risk factor for atherosclerosis
[13] increased significantly after nine days (Table 1). Another
possible risk factor, namely the sphingomyelin/lecithin (SPH/
PC) ratio, however decreased slightly during passive Heymann
nephritis.
As observed in other nephrotic conditions [2, 3, 11] we found
that serum albumin levels were inversely correlated with cho-
lesterol (r —0.83), triglycerides (r = —0.80) and lecithin, the
major phospholipid (r = —0.94, Fig. 4). However, it is of
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Fig. 4. Correlation of serum albumin concentrations with the major
lipids of plasma. Curve fitting was performed on a computer by the least
square regression method using either a linear [plasma cholesterol
(CHOL) and plasma phosphatidyl choline (PC)] or power [plasma
triglycerides (TG)] formula.
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Fig. 5. Lipoprotein profile of plasma from a control rat and a nephrotic (Day 9) rat. The lipoproteins were separated by discontinuous density
gradient ultracentrifugation as described in Methods. The identification of individual lipoprotein peaks is based on the centrifugation profile of the
isolated human plasma lipoproteins under identical conditions. HDL, high density lipoprotein; LDL, low density lipoprotein; LPDS, lipoprotein
deficient serum; VLDL, very low density lipoprotein. Symbols are: (—) A280, (•) cholesterol, (S) triglycerides.
interest to note that while the lecithin and cholesterol levels
increased linearly with decreasing serum albumin concentra-
tion, the triglyceride levels increased in an exponential manner.
A similar non-linear relationship between triglyceride and albu-
min concentration was also reported in human NS [24].
Lipoprotein profiles
In order to determine the effect of passive Heymann nephritis
on the concentrations of various lipoproteins we subjected the
plasma from control (Day 0) and nephrotic (Day 9) animals to
density gradient ultracentrifugation as described in Methods.
The protein (A280), total cholesterol and triglyceride concentra-
tion of the fractions are shown in Figure 5. While a significant
increase was seen in all the lipoprotein fractions, the most
dramatic increase was seen in the VLDL fraction, as also
reflected by the disproportionate increase in plasma TG (Fig. 2,
Table 1). While the control rats have very little LDL in the
plasma, the level of this lipoprotein was markedly elevated after
the induction of nephritis. Quantitatively, most of the increase
in plasma cholesterol was due to an increase in HDL levels,
whereas the TG increase was mostly in the VLDL and the
intermediate density lipoprotein region.
Enzyme activities
The fractional esterification rate (FER) of LCAT was slightly
increased after three days, but fell significantly thereafter (Fig.
6). Thus, the rate after nine days was only half of that on Day
0. On the otherhand, the FER of LAT activity was increased by
about 40% after nine days. In contrast to the FERs, the molar
esterification rates (MERs) of both LCAT and LAT activities
increased after induction of the NS. The increase in the MER of
LCAT reflects the i, ;reased pool size of the free cholesterol
available for esterific ttion, although a smaller percentage of this
pool is esterified compared to the control animals. Since both
activities are carried out by the same protein, it is informative to
look at the ratio of the two activities (LAT/LCAT), as affected
by the NS (Fig. 7). While the ratio of molar rates remained
essentially the same, the ratio of fractional rates increased by
fourfold. The most important factor influencing the ratios is
serum albumin concentration. As shown in Figure 8, the
albumin concentration correlated positively with the FER of
LCAT (r = 0.74), whereas it was negatively correlated (al-
though not statistically significant) with the FER of LAT (r =
—0.37). The ratio of LAT/LCAT was negatively correlated (r =
—0.83) with albumin concentrations, but the relationship was
exponential instead of linear, indicating that when albumin
levels fall below a certain threshold, the ratio of enzyme
activities would be changed drastically. Since increased LDL
levels found In NS would stimulate LAT activity, the ratio is
further influenced in favor of LAT, and this in part, may be
responsible for the nonlinear relationship between albumin
levels and the ratio of activities.
An interesting relationship was observed between the LCAT
rate (FER) and the concentration of esterified cholesterol.
When both the control and nephrotic rats were grouped to-
gether, the relationship between LCAT and esterified choles-
terol did not fit a simple linear or exponential equation. How-
ever, when the results from control and nephrotic rats were
graphed separately, the LCAT rate was positively correlated (r
= 0.87) with plasma esterified cholesterol concentration in
control rats, but negatively correlated (r =
—0.69) in nephrotic
animals (Fig. 9). Similar relationships were observed when total
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Fig. 6. LCAT(•—S) and LAT(O-O) activities during development of
passive Heymann nephritis. The determination of fractional esterifica-
tion rates (A) and the molar esterification rates (B) is described under
Methods. The number of animals studied is the same as in Fig. I and the
values given are mean SD. *P < 0.05, **p < 0.005 when compared to
Day 0 values (t-test).
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Fig. 7. Ratio of LA TILCAT activities during development of nephrotic
syndrome. p < 0.05 compared to Day 0 value (t-test). FER, fractional
esterification rate (A—A); MER, molar esterification rate (O---O).
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Fig. 8. Correlation of serum albumin levels with fractional esterifica-
tion rates (FER's) and the ratios of FER (LATILCA T) in control and
nephrotic animals, grouped together.
=
—0.83)). The LAT rate was not significantly correlated with
plasma cholesterol levels (r = 0.38) or TG levels (r = 0.31).
Discussion
Although hyperlipidemia has been recognized as a basic
feature of the NS for a long time, the underlying mechanisms
for the alterations observed in lipid transport are not clearly
understood. Most studies designed to understand the mecha-
nisms contributing to hyperlipidemia in experimental nephrosis
were carried out with puromycin aminonucleoside-induced NS.
2 3 4 5
cholesterol instead of esterified cholesterol was plotted against
LCAT rates (results not shown). The correlation between free
cholesterol levels and the LCAT FER was negative, fitting an
exponential equation (In FER = (—0.86 [plasma FCI + 2.906) (r
Fig. 9. Relationship between the LCAT (fractional esterification rate) and cholesteryl ester concentration in (A) control and (B) nephrotic rats.
The control group included all animals on Day 0, and the animals injected with non-immune serum. The nephrotic group included animals injected
with anti-FxIA serum and sacrificed on Days 3, 6, or 9.
Whereas this model appears to be comparable to human mini-
mal change disease in children, passive Heymann nephritis is a
better model for the immunologically-mediated NS present in
adults, namely the idiopathic membranous glomerulonephritis
[25]. There is very little information available on the lipid
abnormalities present in passive Heymann nephritis, although
extensive studies have been carried out on the immunopatho-
logical aspects of the disease [12, 14, 21]. Furthermore, the
results obtained from the puromycin aminonucleoside model
cannot necessarily be extrapolated to other nephrotic condi-
tions because of the possible direct effect of the nucleoside on
the liver enzymes involved in lipoprotein metabolism [11]. To
understand the mechanisms of hyperlipidemia secondary to
NS, it is necessary to use a model in which the inducing agent
has no direct effect on enzymes of lipid metabolism. For this
reason, the passive Heymann nephritis model may be better
suited for this purpose.
One of the primary aims of the present study was to deter-
mine the effects of NS and the resulting decline in serum
albumin levels on the two acyltransferase activities carried out
by the plasma enzyme LCAT. The results presented here
clearly show the important regulatory role played by serum
albumin on both cholesterol esterification and lysolecithin es-
terification. While the two reactions take place on the surface of
different lipoproteins, serum albumin activates LCAT by re-
moving the product, lysolecithin, while it inhibits the LAT by
binding the substrate. The dramatic changes in albumin con-
centration achieved over a short period of time during experi-
mental NS provide an unique model to study the physiological
role of albumin in the regulation of the two activities. The
results presented show that the ratio of LAT/LCAT activities
can be increased significantly by the loss of serum albumin.
Furthermore, the increase in plasma LDL, the natural activator
of LAT further distorts the ratios in favor of LAT. What are the
possible consequences of these alterations in the two activities?
We have shown earlier that LAT activity enriches the plasma
with disaturated lecithins, although it does not change the net
concentration of total lecithin [9]. It has been postulated that
the disaturated lecithins increase the adsorption of lipoproteins
to the arterial wall and thus promote atherosclerosis [10].
Therefore, it would be of interest to know if they are increased
in NS due to higher LAT activity, especially in human NS,
where the LDL levels are higher than in rats [1].
The decreased LCAT activity may be at least partly respon-
sible for the increases we observed in the ratios of both the free
cholesterol/esterified cholesterol and free cholesterol/lecithin.
The increase in free cholesterol levels due to lower LCAT
activity may impair the efflux of cholesterol from the cells and
thus retard reverse cholesterol transport and promote athero-
genesis [26]. In fact, the increased free cholesterol/lecithin
ratios has been recently shown to be an independent risk factor
for atherosclerosis [13].
Another consequence of reduced LCAT activity in NS is that
despite the overall increase in plasma esterified cholesterol
levels, the percentage of cholesteryl esters derived from the
LCAT reaction will be reduced. In non-nephrotic rats, the
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LCAT reaction appears to be responsible for the formation of at
least 30% of the total plasma cholesteryl esters [27], whereas in
normal humans almost 100% of the cholesteryl esters may be
derived from this reaction [27, 28]. In nephrosis, these percent-
ages would be expected to be reduced significantly. It is of
interest to note that whereas the cholesteryl ester concentration
in control rats was positively correlated with the LCAT activ-
ity, it was negatively correlated in the nephrotic rats (Fig. 9),
indicating that in the latter case, the source of most of the
cholesteryl esters was non-LCAT mediated. This observation is
also in accordance with the report that in rats the cholesteryl
esters in VLDL are derived from the ACAT (Acyl-CoA:
cholesterol acyltransferase) reaction, whereas those in HDL
are LCAT-derived [29]. Since the increase in VLDL exceeded
that of HDL in passive Heymann nephritis, the majority of the
cholesteryl esters must have been synthesized in the liver or
intestine by the ACAT reaction. Quantitatively, the effects of
NS in humans on the relative contribution of LCAT towards
plasma cholesteryl esters in human NS would be expected to be
greater because LCAT produces most of the cholesteryl esters
in normal plasma.
An important consequence of the diminished contribution of
LCAT would be the changes in the fatty acid composition of
plasma cholesteryl esters. In normal rats for example, most of
the polyunsaturated cholesteryl esters appear to be derived
from the LCAT reaction [28] and therefore in NS the percent-
ages of 20:4, 20:5 and 22:6 esters of cholesterol may be
significantly reduced. Since the LCAT-derived cholesteryl es-
ters may be the major source of polyunsaturated fatty acids for
the gonads and adrenals in rats [29], the functions of these
tissues may be compromised in long-term NS.
Cohen et al [30] reported a significant decrease in LCAT
activity in human NS also and found a positive correlation of
the activity with serum albumin levels. Since human plasma
LCAT produces predominantly cholesteryl linoleate and the
liver and intestinal ACAT produces cholesteryl oleate, the ratio
of cholesteryl oleate/cholesteryl linoleate should be increased in
human NS.
Although the rat is a poor model to study the risk of
atherosclerosis in NS because of its resistance to atherosclero-
sis, the present studies provide indirect evidence that in humans
and other species susceptible to atherosclerosis, NS may in-
crease the risk of atherosclerosis. Thus, the increased levels of
LDL and FC/PC ratios, as shown here, a potential increase in
disaturated lecithin content because of higher LAT, and an
impaired reverse cholesterol transport because of increased
free cholesterol levels are all potentially atherogenic conse-
quences which could result from NS. While the risk of coronary
artery disease in NS has been controversial [5, 31], our results
suggest that further studies are necessary to determine if any or
all of the above risk factors are also present in humans with NS.
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